The Activity, Safety, and Evolving Role of Brigatinib in Patients With ALK-rearranged Non-Small Cell Lung Cancers

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s109295
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.15-10 Determinants of Health Utility Scores (HUS) in Patients With ALK Rearranged Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Brigatinib for ALK-positive Metastatic Non-Small-Cell Lung Cancer: Design, Development and Place in Therapy

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2018English

Tackling ALK in Non-Small Cell Lung Cancer: The Role of Novel Inhibitors

Translational Lung Cancer Research
Oncology
2016English

P2.01-84 Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy